butyrlcholinesterase, human (Recombinant)
Trade name: Protexia
Recombinant proteinexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2007 (NCT00333515)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Acetylcholinesterase and butyrylcholinesterase (AChE and BChE) supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- human butyrylcholinesterase
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00744146 | Phase 1 | Sep 1, 2008 | Department of Defense, IQVIA, PharmAthene, QPS |
| NCT00333528 | Phase 1 | Dec 1, 2007 | Baxalta, DynPort Vaccine Company LLC, IQVIA |
| NCT00333515 | Phase 1 | Jan 1, 2007 | Baxalta, DynPort Vaccine Company LLC, IQVIA |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| IQVIA | For profit | 3 | 0 | 1 | 2007 |
| Baxalta | For profit | 2 | 2 | 1 | 2007 |
| DynPort Vaccine Company LLC | For profit | 2 | 0 | 1 | 2007 |
| Department of Defense | Government | 1 | 0 | 1 | 2008 |
| PharmAthene | For profit | 1 | 1 | 1 | 2008 |
| QPS | For profit | 1 | 0 | 1 | 2008 |
6 organizations
Page 1 / 1